The ADDF (Alzheimer's Drug Discovery Foundation) provides funding to academic centers and biotechnology institutions around the world that promote therapeutic development and biomarkers for Alzheimer's and related dementia. Funding covers several areas:
- Translational research to develop new drugs and build preclinical evidence;
- Studies allowing IND and early stage clinical trials for new and reused medicines;
- Development and validation of biomarkers with plasma, CSF, neuroimaging and digital;
- Epidemiological studies and comparative efficacy research.
Applications are reviewed throughout the year through the core ADDF programs. Regularly return to additional joint funding opportunities with ADDF partners in nonprofits, government and industry.
More details about ADDF and the funding opportunities available can be found at the following link: https://www.alzdiscovery.org/research-and-grants/funding-opportunities